Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Santhera Pharmaceuticals (Schweiz) AG currently has 1 pending office action in its patent portfolio. This portfolio is categorized under the Biotechnology & Pharmaceuticals technology area. The prosecution is managed by 1 distinct examiner across 1 distinct art unit, showing a very specific focus for the company's current intellectual property efforts.
The busiest examiner for Santhera Pharmaceuticals (Schweiz) AG is AULAKH, CHARANJIT, who is currently handling 1 busiest examiner pending office action. Given that the total number of 1 pending office action is assigned to this individual, the examiner is responsible for all active prosecution tasks for the company. The use of 1 distinct art unit further confirms that the pending matter is concentrated within a specific pharmaceutical or biotechnological sub-discipline. This centralized prosecution structure means that the company's immediate patent outcomes are tied to the findings of AULAKH, CHARANJIT within 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AULAKH, CHARANJIT | 1 | 80.7% | -14.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682035 | Synthesis of Delta 9,11 Steroids | AULAKH, CHARANJIT | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682035 | Synthesis of Delta 9,11 Steroids | AULAKH, CHARANJIT | 1621 | §102§112 | Non-Final OA | — | Pending | Feb 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSanthera Pharmaceuticals (Schweiz) AG has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Charanjit Aulakh has the most, with 1 of Santhera Pharmaceuticals (Schweiz) AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
